What Clinicians Want to Know About Toxicity Considerations Associated with BTK Inhibitors
Hematologic Oncology Update09/22/23 • 62 min
Dr Nicole Lamanna from the Columbia University Herbert Irving Comprehensive Cancer Center in New York, New York, and Dr William G Wierda from The University of Texas MD Anderson Cancer Center in Houston, Texas, discuss the spectrum of toxicities associated with BTK inhibitors and strategies for their mitigation and management for patients with chronic lymphocytic leukemia and mantle cell lymphoma.
09/22/23 • 62 min
Generate a badge
Get a badge for your website that links back to this episode
Select type & size
<a href="https://goodpods.com/podcasts/hematologic-oncology-update-70984/what-clinicians-want-to-know-about-toxicity-considerations-associated-33837790"> <img src="https://storage.googleapis.com/goodpods-images-bucket/badges/generic-badge-1.svg" alt="listen to what clinicians want to know about toxicity considerations associated with btk inhibitors on goodpods" style="width: 225px" /> </a>
Copy